Once upon a time, those drugs with "foreign labels" shone in the sky of the pharmaceutical market like stars, and every shot and tablet seemed to be inlaid with sky-high labels, which made people prohibitive. However, with the deepening of medical reform, an "earthquake" in the medical industry is quietly coming. Those original pharmaceutical companies that were once invincible have now been defeated in this change, which is so great and deep in impact that it is really amazing!
According to reports, more than 110 drugs have been ruthlessly eliminated just because they do not meet the conditions for new volume procurement. Among these medicines, there are many "foreign medicines" that were once infinitely beautiful. This change seems to be a reshuffle in the pharmaceutical industry, which makes people wonder: what is going on?
The source of this "earthquake" is the implementation of the volume procurement policy. Medical centralized procurement, as the name suggests, is to reduce the purchase price of drugs through large-scale procurement through bidding, so as to control the expenditure of medical insurance costs. This may sound like a good policy for the benefit of the country and the people, but in practice, it is full of challenges and games.
As a leader in the pharmaceutical market, the original pharmaceutical company has been winning the trust of patients with its unique efficacy and quality. However, under the policy of volume procurement, price has become a key factor in competition. As a result, the original drug gradually lost its advantage in the competition with generic drugs. At the same time, with the continuous progress of domestic generic drug technology and the improvement of quality, generic drugs are more advantageous in price, and they are gradually close to the original drugs in terms of efficacy. This has undoubtedly brought a huge impact to the original pharmaceutical companies.
So, does the collective defeat of the original drug mean that the interests of patients are damaged? While the withdrawal of innovator drugs may be worrying for some patients, the rise of generic drugs has also provided patients with more options. Moreover, with the advancement of technology and the strengthening of regulation, the quality and safety of generic drugs have also been significantly improved. So, in the long run, this change may be able to drive healthy competition in the pharmaceutical market, allowing patients to get better treatment at a lower price.
However, we cannot ignore the value of the original drug. Innovator drugs have unique advantages in R&D and innovation, and they can often lead the development direction of the pharmaceutical industry. Therefore, how to encourage the R&D and innovation of original drugs while ensuring the rationality and sustainability of medical costs is an important issue in front of us.
In the face of this "earthquake" in the pharmaceutical industry, the game between domestic and foreign pharmaceutical companies is becoming more and more intense. Domestic pharmaceutical companies need to seize the opportunity to strengthen their independent R&D and innovation capabilities to improve product quality and competitiveness. At the same time, international pharmaceutical companies are also actively seeking opportunities for cooperation and exchange to cope with market changes. This is undoubtedly an era full of challenges and opportunities.
In this transformation, we also see human emotions and thinking. Innovators who once gave hope to patients are now facing significant challenges, and those who benefit from lower prices are also thinking about how to make trade-offs between efficacy and price. This is undoubtedly a difficult choice, but it is also a question that deserves our attention and consideration.
Finally, I would like to say that although this "earthquake" in the pharmaceutical industry has brought many changes and challenges, it has also provided us with opportunities to think and improve. We should face these changes with a more open mind, actively seek solutions to solve problems, and jointly promote the healthy development of the pharmaceutical industry. At the same time, I also look forward to hearing more readers' opinions and opinions on this topic, so that we can discuss the future of the pharmaceutical industry.
Because in this era, everyone is a witness and a participant, and our choices and actions will determine the future direction of this industry. So, let's work together to create a fairer, more transparent and more efficient pharmaceutical industry.
As for what the impact of this change will be, and will the benefits outweigh the disadvantages, or will the disadvantages outweigh the benefits? But in any case, we should keep our attention and think in order to better respond to the challenges and opportunities of the future.